Table 2 Differences in proportions of patients with abnormally low values at the endpoint of the SIRIUS study
Outcome | Placebo, n/N (proportion) | Mepolizumab, n/N (proportion) | Linear regression | Automated procedure | Empirical estimates | |
|---|---|---|---|---|---|---|
Adjusted¥ mean difference [95% CI], p-value | Adjusted¥ difference in proportion [95% DCI], p-valueΩ | Fisher’s exact test p-value | Difference in proportion [95% CI] | |||
Alanine Aminotransferase(IU/L) | 0/61 (0.00) | 0/66 (0.00) | − 0.71 [− 3.97, 2.56], 0.67 | 0.003 [− 0.01, 0.01], 0.67 | NE | 0.00 [0.00, 0.00] |
Calcium (mmol/L) | 0/61 (0.00) | 1/66 (0.02) | 0.005 [− 0.03, 0.04], 0.85 | − 0.0008 [− 0.005, 0.004], 0.85 | > 0.99 | 0.02 [− 0.01, 0.05] |
Eosinophils (109/L) | 2/62 (0.03) | 27/65 (0.42) | − 0.36 [− 0.43, − 0.28], < 0.01 | 0.48 [0.38, 0.59], < 0.01 | < 0.01 | 0.39 [0.26, 0.52] |
Glucose (mmol/L) | 1/61 (0.02) | 2/66 (0.03) | 0.01 [− 0.34, 0.36], 0.96 | − 0.002 [− 0.07, 0.06], 0.96 | > 0.99 | 0.01 [− 0.04, 0.06] |
Haematocrit (fraction of 1) | 1/62 (0.02) | 4/66 (0.06) | − 0.03 [− 0.04, − 0.01], < 0.01 | 0.02 [0.01, 0.03], < 0.01 | 0.37 | 0.04 [− 0.03, 0.11] |
Haemoglobin (g/L) | 4/62 (0.06) | 8/66 (0.12) | − 8.18 [− 12.73, − 3.62], < 0.01 | 0.06 [0.03, 0.09], < 0.01 | 0.37 | 0.06 [− 0.04, 0.16] |
Lymphocytes/Leukocytes (%) | 12/62 (0.19) | 10/65 (0.15) | 0.69 [− 2.85, 4.22], 0.70 | − 0.02 [− 0.09, 0.05], 0.70 | 0.64 | − 0.04 [− 0.17, 0.09] |
Platelets (109/L) | 0/61 (0.00) | 0/65 (0.00) | 18.75 [− 3.86, 41.37], 0.10 | − 0.004 [− 0.01, 0.002], 0.10 | NE | 0.00 [0.00, 0.00] |
Potassium (mmol/L) | 4/61 (0.07) | 0/66 (0.00) | 0.10 [− 0.003, 0.20], 0.06 | − 0.02 [− 0.03, − 0.001], 0.06 | 0.06 | − 0.07 [− 0.13, − 0.01] |
Sodium (mmol/L) | 0/61 (0.00) | 1/66 (0.02) | − 0.43 [− 1.03, 0.17], 0.16 | 1.41e−15 [− 1.23e−15, 4.04e−15], 0.16 | > 0.99 | 0.02 [− 0.01, 0.05] |